<DOC>
	<DOCNO>NCT01240226</DOCNO>
	<brief_summary>This single-center , open-label , randomize , 2-part study determine relative bioavailability GDC-0941 capsule market-image tablet formulation effect ketoconazole pharmacokinetics GDC-0941 market-image tablet formulation .</brief_summary>
	<brief_title>A Study Determine Relative Bioavailability Tablet Formulation GDC-0941 Effect Ketoconazole Pharmacokinetics GDC-0941 Tablet</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Inclusion Criteria Medically healthy determine absence clinically significant finding physical examination , medical history , vital sign measurement , clinical laboratory test , 12lead electrocardiogram ( ECGs ) For female subject : postmenopausal without recent history menorrhea , surgically sterile use effective method contraception oral transdermal contraceptive , doublebarrier contraception , intrauterine device , depot progesterone , implant contraceptive device , Day 1 45 day study drug completion/discharge ; female subject must negative pregnancy test Screening Day 1 For male subject : sterile sterile sexual partner , agreement use 2 form medically acceptable method contraception , one barrier , agreement donate sperm Screening throughout study period least 3 month last dose study drug . Exclusion Criteria History clinical manifestation significant metabolic ( include type 1 2 diabetes ) , hepatic , renal , hematological , pulmonary , cardiovascular , endocrine , gastrointestinal ( include gastric duodenal ulcer ) , urological , neurological , psychiatric disease , cancer History inflammatory arthritis History symptomatic hypotension History severe physical injury , direct impact trauma , neurological trauma within specify timeframe prior initiation study treatment History seizure disorder History bipolar major depressive disorder History stomach intestinal surgery resection ( except appendectomy , hernia repair , cholecystectomy ) History presence abnormal ECG History ventricular dysrhythmias risk factor ventricular dysrhythmias History alcoholism , drug abuse , drug addiction Use nicotinecontaining nicotinereplacement product within specify timeframe prior initiation study treatment Use medication capable inhibit hepatic enzyme within specify timeframe prior initiation study treatment Participation investigational drug study receipt investigational study drug occur within specify timeframe prior initiation study treatment Use prescription medications/products include monoamine oxidase inhibitor , thioridazine , pimozide , antidepressant within specify timeframe prior initiation study treatment ( 2 week antibiotic ) ( except hormonereplacement therapy 2 week use narcotic pain ) Any vaccination immunization within specify timeframe prior initiation study treatment Routine use PPIs histamine H2receptor antagonist , use drug within specify timeframe prior initiation study treatment Known hypersensitivity ketoconazole azole antifungal Use overthecounter , nonprescription preparation ( include supplement , vitamin , mineral , phytotherapeutic/herbal/plantderived preparation , tryptophan , St. John 's wort ) within specify timeframe prior initiation study treatment Use alcoholcontaining , grapefruitcontaining , caffeinecontaining food beverage within specify timeframe prior initiation study treatment Donated blood within within specified timeframe prior initiation study treatment Received blood product within specify timeframe prior initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>